Literature DB >> 24934793

Effectiveness of screening with annual magnetic resonance imaging and mammography: results of the initial screen from the ontario high risk breast screening program.

Anna M Chiarelli1, Maegan V Prummel2, Derek Muradali2, Vicky Majpruz2, Meaghan Horgan2, June C Carroll2, Andrea Eisen2, Wendy S Meschino2, Rene S Shumak2, Ellen Warner2, Linda Rabeneck2.   

Abstract

PURPOSE: The Ontario Breast Screening Program expanded in July 2011 to screen women age 30 to 69 years at high risk for breast cancer with annual magnetic resonance imaging (MRI) and digital mammography. To the best of our knowledge, this is the first organized screening program for women at high risk for breast cancer. PATIENTS AND METHODS: Performance measures after assessment were compared with screening results for 2,207 women with initial screening examinations. The following criteria were used to determine eligibility: known mutation in BRCA1, BRCA2, or other gene predisposing to a markedly increased risk of breast cancer, untested first-degree relative of a gene mutation carrier, family history consistent with hereditary breast cancer syndrome and estimated personal lifetime breast cancer risk ≥ 25%, or radiation therapy to the chest (before age 30 years and at least 8 years previously).
RESULTS: The recall rate was significantly higher among women who had abnormal MRI alone (15.1%; 95% CI, 13.8% to 16.4%) compared with mammogram alone (6.4%; 95% CI, 5.5% to 7.3%). Of the 35 breast cancers detected (16.3 per 1,000; 95% CI, 11.2 to 22.2), none were detected by mammogram alone, 23 (65.7%) were detected by MRI alone (10.7 per 1,000; 95% CI, 6.7 to 15.8), and 25 (71%) were detected among women who were known gene mutation carriers (30.8 per 1,000, 95% CI, 19.4 to 43.7). The positive predictive value was highest for detection based on mammogram and MRI (12.4%; 95% CI, 7.3% to 19.3%).
CONCLUSION: Screening with annual MRI combined with mammography has the potential to be effectively implemented into an organized breast screening program for women at high risk for breast cancer. This could be considered an important management option for known BRCA gene mutation carriers.
© 2014 by American Society of Clinical Oncology.

Entities:  

Mesh:

Year:  2014        PMID: 24934793     DOI: 10.1200/JCO.2013.52.8331

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  32 in total

1.  Baseline Surveillance in Li-Fraumeni Syndrome Using Whole-Body Magnetic Resonance Imaging: A Meta-analysis.

Authors:  Mandy L Ballinger; Ana Best; Phuong L Mai; Payal P Khincha; Jennifer T Loud; June A Peters; Maria Isabel Achatz; Rubens Chojniak; Alexandre Balieiro da Costa; Karina Miranda Santiago; Judy Garber; Allison F O'Neill; Rosalind A Eeles; D Gareth Evans; Eveline Bleiker; Gabe S Sonke; Marielle Ruijs; Claudette Loo; Joshua Schiffman; Anne Naumer; Wendy Kohlmann; Louise C Strong; Jasmina Bojadzieva; David Malkin; Surya P Rednam; Elena M Stoffel; Erika Koeppe; Jeffrey N Weitzel; Thomas P Slavin; Bita Nehoray; Mark Robson; Michael Walsh; Lorenzo Manelli; Anita Villani; David M Thomas; Sharon A Savage
Journal:  JAMA Oncol       Date:  2017-12-01       Impact factor: 31.777

2.  Utilization of magnetic resonance imaging in breast cancer screening.

Authors:  D Lin; L Moy; D Axelrod; J Smith
Journal:  Curr Oncol       Date:  2015-10       Impact factor: 3.677

3.  Performance Measures of Magnetic Resonance Imaging Plus Mammography in the High Risk Ontario Breast Screening Program.

Authors:  Anna M Chiarelli; Kristina M Blackmore; Derek Muradali; Susan J Done; Vicky Majpruz; Ashini Weerasinghe; Lucia Mirea; Andrea Eisen; Linda Rabeneck; Ellen Warner
Journal:  J Natl Cancer Inst       Date:  2020-02-01       Impact factor: 13.506

Review 4. 

Authors:  Ruth Heisey; June C Carroll
Journal:  Can Fam Physician       Date:  2016-10       Impact factor: 3.275

Review 5.  Identification and management of women with a family history of breast cancer: Practical guide for clinicians.

Authors:  Ruth Heisey; June C Carroll
Journal:  Can Fam Physician       Date:  2016-10       Impact factor: 3.275

6.  Intensive Surveillance with Biannual Dynamic Contrast-Enhanced Magnetic Resonance Imaging Downstages Breast Cancer in BRCA1 Mutation Carriers.

Authors:  Rodrigo Santa Cruz Guindalini; Yonglan Zheng; Hiroyuki Abe; Kristen Whitaker; Toshio F Yoshimatsu; Tom Walsh; David Schacht; Kirti Kulkarni; Deepa Sheth; Marion S Verp; Angela R Bradbury; Jane Churpek; Elias Obeid; Jeffrey Mueller; Galina Khramtsova; Fang Liu; Akila Raoul; Hongyuan Cao; Iris L Romero; Susan Hong; Robert Livingston; Nora Jaskowiak; Xiaoming Wang; Marcio Debiasi; Colin C Pritchard; Mary-Claire King; Gregory Karczmar; Gillian M Newstead; Dezheng Huo; Olufunmilayo I Olopade
Journal:  Clin Cancer Res       Date:  2018-08-28       Impact factor: 12.531

Review 7.  Intensified surveillance for early detection of breast cancer in high-risk patients.

Authors:  Ulrich Bick
Journal:  Breast Care (Basel)       Date:  2015-02       Impact factor: 2.860

8.  Subsequent Breast Cancer in Female Childhood Cancer Survivors in the St Jude Lifetime Cohort Study (SJLIFE).

Authors:  Matthew J Ehrhardt; Carrie R Howell; Karen Hale; Malek J Baassiri; Carol Rodriguez; Carmen L Wilson; Surekha S Joshi; Thomas C Lemond; Sheila Shope; Rebecca M Howell; Zhaoming Wang; Deokumar Srivastava; Daniel A Mulrooney; Jinghui Zhang; Leslie L Robison; Kirsten K Ness; Melissa M Hudson
Journal:  J Clin Oncol       Date:  2019-05-10       Impact factor: 44.544

Review 9.  Inequities in genetic testing for hereditary breast cancer: implications for public health practice.

Authors:  Ambreen Sayani
Journal:  J Community Genet       Date:  2018-05-20

Review 10.  Ultrasound as an Adjunct to Mammography for Breast Cancer Screening: A Health Technology Assessment.

Authors: 
Journal:  Ont Health Technol Assess Ser       Date:  2016-07-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.